Literature DB >> 9378386

K-ras mutations in patients with early colorectal cancers.

H J Andreyev1, J V Tilsed, D Cunningham, S A Sampson, A R Norman, H J Schneider, P A Clarke.   

Abstract

BACKGROUND: Published data are contradictory about the importance of K-ras mutations in advanced tumours and are not available for early cancers. AIMS: To establish whether specific K-ras mutations are prognostic markers in early stage colorectal adenocarcinoma.
METHODS: The presence of K-ras exon 1 mutations were correlated with tumour recurrence in two groups of patients: group 1 was a consecutive series of patients with resected colorectal adenocarcinoma at low risk of recurrence; group 2 were patients referred for chemotherapy after relapse of previously resected early stage tumours. K-ras mutations were detected by direct sequencing of whole tissue samples in all patients and in some, the leading edge and centre of the tumour were also microdissected out individually and sequenced.
RESULTS: Mutations were present in 26 (26.5%) of 98 patients in group 1; 14 patients developed a recurrence, four (28.5%) of whom had a K-ras mutation. Seventy nine patients have not developed tumour recurrence, 22 (28%) of whom had a mutation (p = 0.84). K-ras mutations were present in five of 14 patients in group 2. Microdissection did not increase the number of mutations detected.
CONCLUSIONS: Individual K-ras genotypes are distributed homogeneously throughout early stage colorectal adenocarcinomas, but detection of a mutation has no apparent prognostic value.

Entities:  

Mesh:

Year:  1997        PMID: 9378386      PMCID: PMC1891500          DOI: 10.1136/gut.41.3.323

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA.

Authors:  T Mukhopadhyay; M Tainsky; A C Cavender; J A Roth
Journal:  Cancer Res       Date:  1991-03-15       Impact factor: 12.701

2.  The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation.

Authors:  M D Sklar
Journal:  Science       Date:  1988-02-05       Impact factor: 47.728

3.  Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene.

Authors:  J P McGrath; D J Capon; D H Smith; E Y Chen; P H Seeburg; D V Goeddel; A D Levinson
Journal:  Nature       Date:  1983 Aug 11-17       Impact factor: 49.962

4.  ras and p53 in the prediction of survival in Dukes' stage B colorectal carcinoma.

Authors:  M A Bennett; E W Kay; H Mulcahy; L O'flaherty; D P O'donoghue; M Leader; D T Croke
Journal:  Clin Mol Pathol       Date:  1995-12

5.  Prevalence of G-to-T transversions among K-ras oncogene mutations in human colorectal tumors in Yugoslavia.

Authors:  N Urosević; K Krtolica; A Skaro-Milić; S Knezević-Usaj; A Dujić
Journal:  Int J Cancer       Date:  1993-05-08       Impact factor: 7.396

6.  Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver.

Authors:  J J Oudejans; R J Slebos; F A Zoetmulder; W J Mooi; S Rodenhuis
Journal:  Int J Cancer       Date:  1991-12-02       Impact factor: 7.396

7.  The common molecular genetic alterations in Dukes' B and C colorectal carcinomas are not short-term prognostic indicators of survival.

Authors:  B R Dix; P Robbins; R Soong; D Jenner; A K House; B J Iacopetta
Journal:  Int J Cancer       Date:  1994-12-15       Impact factor: 7.396

8.  Mutant K-ras oncogenes in colon cancers Do not predict Patient's chemotherapy response or survival

Authors: 
Journal:  Clin Cancer Res       Date:  1995-04       Impact factor: 12.531

Review 9.  An approach for new anticancer drugs: oncogene-targeted antisense DNA.

Authors:  G Schwab; I Duroux; C Chavany; C Hélène; E Saison-Behmoaras
Journal:  Ann Oncol       Date:  1994       Impact factor: 32.976

10.  Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells.

Authors:  T Kinoshita; T Yokota; K Arai; A Miyajima
Journal:  Oncogene       Date:  1995-06-01       Impact factor: 9.867

View more
  13 in total

1.  Ras mutation impairs epithelial barrier function to a wide range of nonelectrolytes.

Authors:  James M Mullin; James M Leatherman; Mary Carmen Valenzano; Erika Rendon Huerta; Jon Verrechio; David M Smith; Karen Snetselaar; Mantao Liu; Mary Kay Francis; Christian Sell
Journal:  Mol Biol Cell       Date:  2005-09-21       Impact factor: 4.138

2.  Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma.

Authors:  H J Andreyev; P J Ross; D Cunningham; P A Clarke
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

3.  A prospective study of circulating mutant KRAS2 in the serum of patients with colorectal neoplasia: strong prognostic indicator in postoperative follow up.

Authors:  B M Ryan; F Lefort; R McManus; J Daly; P W N Keeling; D G Weir; D Kelleher
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

4.  APC and K-ras gene mutation in aberrant crypt foci of human colon.

Authors:  P Yuan; M H Sun; J S Zhang; X Z Zhu; D R Shi
Journal:  World J Gastroenterol       Date:  2001-06       Impact factor: 5.742

5.  IMP-1 displays cross-talk with K-Ras and modulates colon cancer cell survival through the novel proapoptotic protein CYFIP2.

Authors:  Perry S Mongroo; Felicite K Noubissi; Miriam Cuatrecasas; Jiri Kalabis; Catrina E King; Cameron N Johnstone; Mark J Bowser; Antoni Castells; Vladimir S Spiegelman; Anil K Rustgi
Journal:  Cancer Res       Date:  2011-01-20       Impact factor: 12.701

6.  Frequency of p16(INK4A) alterations and K-ras mutations in intrahepatic cholangiocarcinoma of the liver.

Authors:  A Tannapfel; M Benicke; A Katalinic; D Uhlmann; F Köckerling; J Hauss; C Wittekind
Journal:  Gut       Date:  2000-11       Impact factor: 23.059

7.  Alterations in K-ras, APC and p53-multiple genetic pathway in colorectal cancer among Indians.

Authors:  Pooja Malhotra; Mumtaz Anwar; Neha Nanda; Rakesh Kochhar; Jai Dev Wig; Kim Vaiphei; Safrun Mahmood
Journal:  Tumour Biol       Date:  2013-03-24

8.  Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics.

Authors:  Vassiliki Kotoula; Elpida Charalambous; Bart Biesmans; Andigoni Malousi; Eleni Vrettou; George Fountzilas; George Karkavelas
Journal:  PLoS One       Date:  2009-11-04       Impact factor: 3.240

9.  Implications of KRAS mutation status for the treatment of metastatic colorectal cancer.

Authors:  Fortunato Ciardiello; Sabine Tejpar; Demetris Papamichael
Journal:  Target Oncol       Date:  2009-11-14       Impact factor: 4.493

10.  Targeted therapies in colorectal cancer-an integrative view by PPPM.

Authors:  Suzanne Hagan; Maria C M Orr; Brendan Doyle
Journal:  EPMA J       Date:  2013-01-28       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.